Management of aggressive pituitary adenomas is challenging due to a paucity of rigorous evidence supporting available treatment approaches. Recent guidelines emphasize the need to maximize standard therapies as well as the use of temozolomide and radiation therapy to treat disease recurrence. However, often these adenomas continue to progress over time, necessitating the use of additional targeted therapies which also impact quality of life and long-term outcomes. In this review, we present 9 cases of aggressive pituitary adenomas to illustrate the importance of a multidisciplinary, individualized approach. The timing and rationale for surgery, radiation therapy, temozolomide, somatostatin receptor ligands, and EGFR, VEGF, and mTOR inhibito...
Pituitary carcinomas are rare tumors with heterogeneous behaviors. Their carcinogenesis is still unk...
Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until identifi...
The clinical course of pituitary adenoma can be highly variable. Aggressive pituitary tumours may re...
INTRODUCTION: Aggressive tumors of the pituitary gland are classically defined as pituitary tumors w...
Background: Although pituitary adenomas are considered benign lesions, a small group may exhibit a c...
BACKGROUND: Pituitary adenomas are usually considered benign tumours, although some of them can exh...
Introduction. Pituitary adenomas comprise 10–15 % of all intracranial tumors. Despite being benign t...
BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most ...
Knowledge about epidemiological, clinical, molecular and pathological characteristics of pituitary a...
International audienceAggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary ...
Background and Importance: In the last eight years temozolomide (TMZ) has been used as the last-line...
Pituitary carcinomas are rare tumors with heterogeneous behaviors. Their carcinogenesis is still unk...
Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until identifi...
The clinical course of pituitary adenoma can be highly variable. Aggressive pituitary tumours may re...
INTRODUCTION: Aggressive tumors of the pituitary gland are classically defined as pituitary tumors w...
Background: Although pituitary adenomas are considered benign lesions, a small group may exhibit a c...
BACKGROUND: Pituitary adenomas are usually considered benign tumours, although some of them can exh...
Introduction. Pituitary adenomas comprise 10–15 % of all intracranial tumors. Despite being benign t...
BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most ...
Knowledge about epidemiological, clinical, molecular and pathological characteristics of pituitary a...
International audienceAggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary ...
Background and Importance: In the last eight years temozolomide (TMZ) has been used as the last-line...
Pituitary carcinomas are rare tumors with heterogeneous behaviors. Their carcinogenesis is still unk...
Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until identifi...
The clinical course of pituitary adenoma can be highly variable. Aggressive pituitary tumours may re...